Last reviewed · How we verify
Lopinavir/ritonavir simplification strategy
Lopinavir/ritonavir simplification strategy is a Protease inhibitor combination Small molecule drug developed by Fundación Huésped. It is currently FDA-approved for HIV-1 infection (as part of antiretroviral therapy simplification strategy). Also known as: Kaletra monotherapy simplification strategy.
A treatment strategy that simplifies HIV management by optimizing the dosing or administration of lopinavir/ritonavir, a protease inhibitor combination, to improve adherence and reduce pill burden.
A treatment strategy that simplifies HIV management by optimizing the dosing or administration of lopinavir/ritonavir, a protease inhibitor combination, to improve patient adherence and outcomes. Used for HIV-1 infection (as part of antiretroviral therapy simplification).
At a glance
| Generic name | Lopinavir/ritonavir simplification strategy |
|---|---|
| Also known as | Kaletra monotherapy simplification strategy |
| Sponsor | Fundación Huésped |
| Drug class | Protease inhibitor combination |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Lopinavir/ritonavir is a fixed-dose combination of two HIV protease inhibitors; lopinavir inhibits viral protease and ritonavir acts as a pharmacokinetic booster. This simplification strategy aims to reduce the complexity of antiretroviral regimens, potentially through dose optimization or formulation changes, to enhance patient adherence and clinical outcomes in HIV-infected individuals.
Approved indications
- HIV-1 infection (as part of antiretroviral therapy simplification strategy)
Common side effects
- Diarrhea
- Nausea
- Lipid abnormalities
- Hepatotoxicity
- Gastrointestinal disturbance
Key clinical trials
- 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients (PHASE3)
- Induction-maintenance of Lopinavir/r in HIV-infected Subjects (PHASE4)
- Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lopinavir/ritonavir simplification strategy CI brief — competitive landscape report
- Lopinavir/ritonavir simplification strategy updates RSS · CI watch RSS
- Fundación Huésped portfolio CI
Frequently asked questions about Lopinavir/ritonavir simplification strategy
What is Lopinavir/ritonavir simplification strategy?
How does Lopinavir/ritonavir simplification strategy work?
What is Lopinavir/ritonavir simplification strategy used for?
Who makes Lopinavir/ritonavir simplification strategy?
Is Lopinavir/ritonavir simplification strategy also known as anything else?
What drug class is Lopinavir/ritonavir simplification strategy in?
What development phase is Lopinavir/ritonavir simplification strategy in?
What are the side effects of Lopinavir/ritonavir simplification strategy?
What does Lopinavir/ritonavir simplification strategy target?
Related
- Drug class: All Protease inhibitor combination drugs
- Target: All drugs targeting HIV protease
- Manufacturer: Fundación Huésped — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for HIV-1 infection (as part of antiretroviral therapy simplification strategy)
- Also known as: Kaletra monotherapy simplification strategy
- Compare: Lopinavir/ritonavir simplification strategy vs similar drugs
- Pricing: Lopinavir/ritonavir simplification strategy cost, discount & access